Dual roles of PGE 2 -EP4 signaling in mouse experimental autoimmune encephalomyelitis
- 21 June 2010
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (27) , 12233-12238
- https://doi.org/10.1073/pnas.0915112107
Abstract
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS). Although prostaglandin (PG) concentrations are increased in cerebrospinal fluid of MS patients, the role of PGs in MS is unknown. We examined this issue by subjecting mice deficient in each PG receptor type or subtype to EAE induction and using agonists or antagonists selective for each of the four PGE receptor (EP) subtypes. Among PG receptor-deficient mice, only EP4−/− mice manifested significant suppression of EAE, which was mimicked in wild-type mice and to a greater extent, in EP2−/− mice by administration of the EP4 antagonist ONO-AE3-208 during the immunization phase. EP4 antagonism during immunization also suppressed the generation of antigen-specific T helper (Th) 1 and Th17 cells in wild-type mice and to a greater extent, in EP2−/− mice. ONO-AE3-208 administration at EAE onset had little effect on disease severity, and its administration throughout the experimental period did not cause significant reduction of the peak of disease, suggesting that, in addition to its facilitative action during the immunization phase, EP4 exerts a preventive action in the elicitation phase. Administration of the EP4 agonist ONO-AE1-329 at EAE onset delayed and suppressed disease progression as well as inhibited the associated increase in permeability of the blood–brain barrier. Thus, PGE2 exerts dual functions in EAE, facilitating Th1 and Th17 cell generation redundantly through EP4 and EP2 during immunization and attenuating invasion of these cells into the brain by protecting the blood–brain barrier through EP4.Keywords
This publication has 45 references indexed in Scilit:
- Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosisProceedings of the National Academy of Sciences, 2009
- IL-17 and Th17 CellsAnnual Review of Immunology, 2009
- Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signalingThe Journal of Experimental Medicine, 2009
- Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansionBlood, 2008
- A rush to judgment on Th17The Journal of Experimental Medicine, 2008
- Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple SclerosisThe American Journal of Pathology, 2008
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007
- Contribution of Poly(ADP-Ribose) Polymerase to Postischemic Blood—Brain Barrier Damage in RatsJournal of Cerebral Blood Flow & Metabolism, 2007
- Loss of blood–brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse modelsProceedings of the National Academy of Sciences, 2007
- Patent Ductus Arteriosus and Neonatal Death in Prostaglandin Receptor EP4-Deficient MiceBiochemical and Biophysical Research Communications, 1998